Calamos Advisors LLC Exagen Inc. Transaction History

Calamos Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$8.97 - $14.08 $105,558 - $165,693	-11,768 Closed	0 $0
Q3 2021 Oct 26, 2021	SELL	$10.25 - $15.21 $157,573 - $233,823	-15,373 Reduced 56.64%	11,768 $160,000
Q2 2021 Jul 22, 2021	SELL	$12.4 - $17.92 $989,594 - $1.43 Million	-79,806 Reduced 74.62%	27,141 $407,000
Q1 2021 Apr 12, 2021	BUY	$13.9 - $22.0 $1.49 Million - $2.35 Million	106,947 New	106,947 $1.87 Million
Q4 2020 Jan 27, 2021	SELL	$11.19 - $16.05 $195,534 - $280,457	-17,474 Closed	0 $0
Q3 2020 Oct 26, 2020	SELL	$10.56 - $16.69 $351,859 - $556,110	-33,320 Reduced 65.6%	17,474 $189,000
Q2 2020 Jul 27, 2020	SELL	$11.0 - $16.7 $751,047 - $1.14 Million	-68,277 Reduced 57.34%	50,794 $631,000
Q1 2020 Apr 28, 2020	SELL	$12.7 - $25.95 $1.24 Million - $2.54 Million	-97,731 Reduced 45.08%	119,071 $1.9 Million
Q4 2019 Jan 15, 2020	BUY	$12.61 - $28.48 $842,663 - $1.9 Million	66,825 Added 44.56%	216,802 $5.51 Million
Q3 2019 Oct 21, 2019	BUY	$14.5 - $17.5 $2.17 Million - $2.62 Million	149,977 New	149,977 $2.32 Million

6.41M

4.5K

400

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $89.8M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Calamos Advisors LLC with notifications on news.